Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Epcoritamab SC Monotherapy Leads to Deep and Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma: First Data Disclosure from the Epcore NHL-1 Follicular Lymphoma Dose-Expansion Cohort

Blood (2023) 142 (Supplement 1): 1655.

https://doi.org/10.1182/blood-2023-179887

Published: 2023

Journal Articles

Updates from Ongoing, First-in-Human Phase 1 Dose Escalation and Expansion Study of TTI-621, a Novel Biologic Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies

Blood (2021) 138 (Supplement 1): 2448.

https://doi.org/10.1182/blood-2021-154490

Published: 2021

Journal Articles

Safety and Efficacy of Tenalisib Given in Combination with Romidepsin in Patients with Relapsed/Refractory T-Cell Lymphoma: Final Results from a Phase I/II Open Label Multi-Center Study

Swaminathan P Iyer, Auris Huen, Weiyun Z. Ai, Deepa Jagadeesh, Mary Jo Lechowicz, Craig Okada, Tatyana A. Feldman, Suchitra Sundaram, Juan Pablo Alderuccio, Nishitha Reddy, Don Stevens, Timothy M. Kuzel, Ann Mohrbacher, Kasi Viswanath Routhu, Prajak Barde, Ajit Mohanchandran Nair, Brad M. Haverkos

Blood (2021) 138 (Supplement 1): 1365.

https://doi.org/10.1182/blood-2021-145851

Published: 2021

Journal Articles

A Multi-Center, Open Label, Phase I/II Study to Assess the Safety and Efficacy of Tenalisib Given in Combination with Romidepsin in Patients with Relapsed/Refractory T-Cell Lymphoma

Swami P. Iyer, MD, Auris Huen, MD, Bradley Haverkos, MD MPH, MS, Weiyun Z. Ai, Craig Okada, MD PhD, Timothy M. Kuzel, MD, Mary Jo Lechowicz, MD, Juan Pablo Alderuccio, MD, Ann Mohrbacher, MD, Don A. Stevens, MD, Ryan A. Wilcox, MD, Tatyana A. Feldman, MD, Suchitra Sundaram, MD, Deepa Jagadeesh, MDMPH, Nishitha Reddy, MD MSCI, Kasi Viswanath Routhu, PhD, Prajak Barde, MD, Ajit Mohanchandran Nair, PhD

Blood (2020) 136 (Supplement 1): 8–10.

https://doi.org/10.1182/blood-2020-136018

Published: 2020

Journal Articles

Updates from Ongoing, First-in-Human Phase 1 Dose Escalation and Expansion Study of TTI-621, a Novel Biologic Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies

Blood (2020) 136 (Supplement 1): 41–43.

https://doi.org/10.1182/blood-2020-136198

Published: 2020

Journal Articles

Long Term Follow-up of a Phase 2 Study Examining Intratumoral G100 Alone and in Combination with Pembrolizumab in Patients with Follicular Lymphoma

Blood (2018) 132 (Supplement 1): 2892.

https://doi.org/10.1182/blood-2018-99-117932

Published: 2018

Journal Articles

Pevonedistat, a Small Molecule Inhibitor of NEDD8-Activating Enzyme (NAE), Induces Cell Cycle Deregulation, Anaphase Catastrophe, and Apoptosis in T-Cell Lymphoma Cells

Adam Kittai, MD, Scott R Best, BS, Taylor Rowland, BS, Nur Bruss, BS, Craig Okada, MD PhD, Alexey V Danilov, MD PhD

Blood (2018) 132 (Supplement 1): 1667.

https://doi.org/10.1182/blood-2018-99-113179

Published: 2018

Journal Articles

Intratumoral G100 Induces Systemic Immunity and Abscopal Tumor Regression in Patients with Follicular Lymphoma: Results of a Phase 1/ 2 Study Examining G100 Alone and in Combination with Pembrolizumab

Blood (2017) 130 (Supplement 1): 2771.

https://doi.org/10.1182/blood.V130.Suppl_1.2771.2771

Published: 2017

Journal Articles

Consolidative Autologous Stem Cell Transplant for Double Hit Lymphoma

Andy I Chen, MDPhD, Craig Okada, MD PhD, Nate Gay, MD, Phil Reiss, MD, Stephen Spurgeon, MD, Guang Fan, MD PhD, Rita M. Braziel, MD, Richard T. Maziarz, MD

Blood (2014) 124 (21): 3993.

https://doi.org/10.1182/blood.V124.21.3993.3993

Published: 2014

Journal Articles

Prognostic Features, Treatments, and Disease-Specific Mortality Among Patients with Diffuse Large B-Cell Lymphoma Over the Age of 75: A Single-Center Retrospective Analysis

Stephen D. Smith, MD, Craig Okada, MD, PhD, Andy I. Chen, MD, PhD, Stephen E Spurgeon, MD, Guang Fan, MD, PhD, Jennifer B Dunlap, MD, Nicky Leeborg, MD, Rita M. Braziel, MD, Richard T. Maziarz, MD

Blood (2012) 120 (21): 3673.

https://doi.org/10.1182/blood.V120.21.3673.3673

Published: 2012

Journal Articles

A Phase I/II Study of Vorinostat (SAHA), Cladribine (2-CdA), and Rituximab Shows Significant Activity in Previously Untreated Mantle Cell Lymphoma

Stephen Spurgeon, MD, Andy I Chen, MD, PhD, Craig Okada, MD, PhD, Samir Parekh, MD, Violetta V. Leshchenko, PhD, Gundula Palmbach, Bashi Ratterree, RN, Nan Subbiah, Christine Capper, RN, Elliot M Epner, MD, PhD

Blood (2011) 118 (21): 441.

https://doi.org/10.1182/blood.V118.21.441.441

Published: 2011

Journal Articles

Cladribine Plus Rituximab Is An Effective Therapy for Newly Diagnosed Mantle Cell Lymphoma

Stephen Spurgeon, MD, Talia Pindyck, MD, Marc M Loriaux, MD, PhD, Craig Okada, MD, PhD, Kamal Abbi, Yiyi Chen, Zunqui Chen, Elana Mater, Elliott Epner, MD, PhD

Blood (2010) 116 (21): 4910.

https://doi.org/10.1182/blood.V116.21.4910.4910

Published: 2010

Journal Articles

Gene expression and angiotropism in primary CNS lymphoma

James L. Rubenstein, Jane Fridlyand, Arthur Shen, Ken Aldape, David Ginzinger, Tracy Batchelor, Patrick Treseler, Mitchel Berger, Michael McDermott, Michael Prados, Jon Karch, Craig Okada, William Hyun, Seema Parikh, Chris Haqq, Marc Shuman

Blood (2006) 107 (9): 3716–3723.

https://doi.org/10.1182/blood-2005-03-0897

Published: 2006

Includes: Supplemental data

NARROW

Epcoritamab SC Monotherapy Leads to Deep and Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma: First Data Disclosure from the Epcore NHL-1 Follicular Lymphoma Dose-Expansion Cohort

Updates from Ongoing, First-in-Human Phase 1 Dose Escalation and Expansion Study of TTI-621, a Novel Biologic Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies

Safety and Efficacy of Tenalisib Given in Combination with Romidepsin in Patients with Relapsed/Refractory T-Cell Lymphoma: Final Results from a Phase I/II Open Label Multi-Center Study

A Multi-Center, Open Label, Phase I/II Study to Assess the Safety and Efficacy of Tenalisib Given in Combination with Romidepsin in Patients with Relapsed/Refractory T-Cell Lymphoma

Updates from Ongoing, First-in-Human Phase 1 Dose Escalation and Expansion Study of TTI-621, a Novel Biologic Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies

Long Term Follow-up of a Phase 2 Study Examining Intratumoral G100 Alone and in Combination with Pembrolizumab in Patients with Follicular Lymphoma

Pevonedistat, a Small Molecule Inhibitor of NEDD8-Activating Enzyme (NAE), Induces Cell Cycle Deregulation, Anaphase Catastrophe, and Apoptosis in T-Cell Lymphoma Cells

Intratumoral G100 Induces Systemic Immunity and Abscopal Tumor Regression in Patients with Follicular Lymphoma: Results of a Phase 1/ 2 Study Examining G100 Alone and in Combination with Pembrolizumab

Consolidative Autologous Stem Cell Transplant for Double Hit Lymphoma

Prognostic Features, Treatments, and Disease-Specific Mortality Among Patients with Diffuse Large B-Cell Lymphoma Over the Age of 75: A Single-Center Retrospective Analysis

A Phase I/II Study of Vorinostat (SAHA), Cladribine (2-CdA), and Rituximab Shows Significant Activity in Previously Untreated Mantle Cell Lymphoma

Cladribine Plus Rituximab Is An Effective Therapy for Newly Diagnosed Mantle Cell Lymphoma

Gene expression and angiotropism in primary CNS lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only